Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23983825 | 0.97 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL26973551 | 0.92 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL21736009 | 0.91 | KDM4E (0.38) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL21735980 | 0.91 | KDM4E (0.38) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL23129461 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL23984333 | 0.90 | CA12 (0.32) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL21736018 | 0.89 | KDM4E (0.38) | SMN1; SMN2LMNAKDM4EATML3MBTL1 | |
| SCHEMBL23129149 | 0.88 | TDP1 (0.30) | L3MBTL1 | |
| SCHEMBL26973596 | 0.88 | CHEK2 (0.32) | — | |
| SCHEMBL26973573 | 0.88 | MAP4K4 (0.32) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | LG CHEM, LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | LG CHEM, LTD. (KR) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340159-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | NR4A1, CYP1A1, ARNT | SMN1; SMN2 3985/4885LMNA 2919/4885KDM4E 2596/4885 |
| US-11858947-B2 | Heterocyclic compound and organic light emitting device including the same | NR4A1, CYP1A1, ARNT | SMN1; SMN2 3985/4885LMNA 2919/4885KDM4E 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.